JP2012523417A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523417A5
JP2012523417A5 JP2012504760A JP2012504760A JP2012523417A5 JP 2012523417 A5 JP2012523417 A5 JP 2012523417A5 JP 2012504760 A JP2012504760 A JP 2012504760A JP 2012504760 A JP2012504760 A JP 2012504760A JP 2012523417 A5 JP2012523417 A5 JP 2012523417A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
lcvr
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012504760A
Other languages
English (en)
Other versions
JP5759977B2 (ja
JP2012523417A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030039 external-priority patent/WO2010117980A1/en
Publication of JP2012523417A publication Critical patent/JP2012523417A/ja
Publication of JP2012523417A5 publication Critical patent/JP2012523417A5/ja
Application granted granted Critical
Publication of JP5759977B2 publication Critical patent/JP5759977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 軽鎖可変領域(LCVR)および重鎖可変領域(HCVR)を含み、LCVRが相補的決定領域(CDR)LCDR1、LCDR2、およびLCDR3を含み、HCVRがCDR HCDR1、HCDR2、およびHCDR3を含み、LCDR1が配列番号5のアミノ酸配列を有し、LCDR2が配列番号47のアミノ酸配列を有し、LCDR3が配列番号49のアミノ酸配列を有し、HCDR1が配列番号1のアミノ酸配列を有し、HCDR2が配列番号2のアミノ酸配列を有し、HCDR3が配列番号44のアミノ酸配列を有する
    ヒト遺伝子操作DKK−1抗体。
  2. LCVRが配列番号52のアミノ酸配列を含み、HCVRが配列番号51のアミノ酸配列を含む、請求項1記載のヒト遺伝子操作DKK−1抗体。
  3. LCDR2が配列番号8のアミノ酸配列を有し、LCDR3が配列番号7のアミノ酸配列を有し、HCDR3が配列番号4のアミノ酸配列を有する請求項1記載のヒト遺伝子操作DKK−1抗体。
  4. 該LCVRおよび該HCVRが、以下の(i)〜(iv):
    (i)該LCVRが配列番号13のアミノ酸配列を含み、該HCVRが配列番号11のアミノ酸配列を含む;
    (ii)該LCVRが配列番号14のアミノ酸配列を含み、該HCVRが配列番号12のアミノ酸配列を含む;
    (iii)該LCVRが配列番号15のアミノ酸配列を含み、該HCVRが配列番号11のアミノ酸配列を含む;
    (iv)該LCVRが配列番号16のアミノ酸配列を含み、該HCVRが配列番号11のアミノ酸配列を含む;
    からなる群より選択されるアミノ酸配列を含む、請求項に記載のヒト遺伝子操作DKK−1抗体。
  5. 該LCVRが配列番号14のアミノ酸配列を含み、該HCVRが配列番号12のアミノ酸配列を含む、請求項に記載のヒト遺伝子操作DKK−1抗体。
  6. 以下の(a)〜(d):
    (a)該重鎖が配列番号17のアミノ酸配列を含み、該軽鎖が配列番号19のアミノ酸配列を含む、
    (b)該重鎖が配列番号18のアミノ酸配列を含み、該軽鎖が配列番号20のアミノ酸配列を含む、
    (c)該重鎖が配列番号17のアミノ酸配列を含み、該軽鎖が配列番号21のアミノ酸配列を含む、および
    (d)該重鎖が配列番号17のアミノ酸配列を含み、該軽鎖が配列番号22のアミノ酸配列を含む、
    からなる群より選択される該重鎖および該軽鎖のアミノ酸配列を含む請求項に記載のヒト遺伝子操作DKK−1抗体。
  7. 各軽鎖が配列番号20のアミノ酸配列を含む2本の軽鎖、および、各重鎖が配列番号18のアミノ酸配列を含む2本の重鎖、を含むヒト遺伝子操作DKK−1抗体。
  8. 請求項1または6に記載のヒト遺伝子操作DKK−1抗体、および、医薬的に許容される担体、希釈剤、または賦形剤を含む、医薬組成物。
  9. 骨の治癒の治療に用いるための、請求項8に記載の組成物
  10. 癌の治療に用いるための、請求項8に記載の組成物
  11. 該癌、多発性骨髄腫、乳癌、および非小細胞肺癌からなる群より選択される請求項10に記載の組成物
  12. 請求項7に記載のヒト遺伝子操作DKK−1抗体、および医薬的に許容される担体、希釈剤、または賦形剤を含む、医薬組成物。
  13. 骨の治癒の治療に用いるための、請求項12に記載の組成物
  14. 癌の治療に用いるための、請求項12に記載の組成物
  15. 該癌が、多発性骨髄腫、乳癌、および非小細胞肺癌からなる群より選択される、請求項14に記載の組成物
JP2012504760A 2009-04-10 2010-04-06 Dkk−1抗体 Active JP5759977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
US61/168,411 2009-04-10
PCT/US2010/030039 WO2010117980A1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (3)

Publication Number Publication Date
JP2012523417A JP2012523417A (ja) 2012-10-04
JP2012523417A5 true JP2012523417A5 (ja) 2013-05-16
JP5759977B2 JP5759977B2 (ja) 2015-08-05

Family

ID=42199718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504760A Active JP5759977B2 (ja) 2009-04-10 2010-04-06 Dkk−1抗体

Country Status (30)

Country Link
US (1) US8148498B2 (ja)
EP (3) EP2930184B1 (ja)
JP (1) JP5759977B2 (ja)
KR (3) KR101461362B1 (ja)
CN (1) CN102388065B (ja)
AR (1) AR075989A1 (ja)
AU (1) AU2010234611B2 (ja)
BR (1) BRPI1014157B1 (ja)
CA (1) CA2758252C (ja)
CY (3) CY1119399T1 (ja)
DK (3) DK2930184T3 (ja)
EA (1) EA021401B1 (ja)
ES (3) ES2728911T3 (ja)
HR (3) HRP20171400T1 (ja)
HU (3) HUE034625T2 (ja)
IL (1) IL214845A (ja)
LT (3) LT2417158T (ja)
ME (2) ME03378B (ja)
MX (1) MX2011010707A (ja)
NZ (1) NZ595011A (ja)
PL (3) PL2930184T3 (ja)
PT (3) PT2417158T (ja)
RS (3) RS62214B1 (ja)
SG (1) SG175244A1 (ja)
SI (3) SI2930184T1 (ja)
TR (1) TR201907261T4 (ja)
TW (1) TWI546079B (ja)
UA (1) UA103916C2 (ja)
WO (1) WO2010117980A1 (ja)
ZA (1) ZA201107256B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131185A1 (en) 2009-05-12 2010-11-18 Pfizer Inc. Blocking anti-dkk-1 antibodies and their uses
ES2780398T3 (es) 2012-12-10 2020-08-25 Biogen Ma Inc Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
BR112017020610A2 (pt) 2015-05-18 2018-07-17 Lilly Co Eli Compostos de anticorpo biespecífico anti-dkk-1- anti-rankl
CN108137702B (zh) * 2015-08-28 2023-01-06 艾利妥 抗siglec-7抗体及其使用方法
SI3370768T1 (sl) * 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
RU2019115946A (ru) * 2016-10-26 2020-11-27 Лип Терапьютикс, Инк. Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1
CN113395978A (zh) * 2018-07-11 2021-09-14 动量制药公司 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
CA3151228A1 (en) 2019-09-19 2021-03-25 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
JP2023502666A (ja) 2019-11-22 2023-01-25 リープ セラピューティクス,インコーポレイテッド Dkk-1阻害剤を用いて癌を処置する方法
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
EP4288098A1 (en) * 2021-02-05 2023-12-13 Omeros Corporation Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
WO2024015463A1 (en) 2022-07-12 2024-01-18 Leap Therapeutics, Inc. Combination therapy
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE353964T1 (de) 1997-04-16 2007-03-15 Millennium Pharm Inc Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
WO2001057190A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL158750A0 (en) 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
WO2003053215A2 (en) 2001-11-07 2003-07-03 The Board Of Trustees Of The University Of Arkansas Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
WO2005028678A2 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
EP2336177A1 (en) 2004-08-04 2011-06-22 Amgen, Inc Antibodies to DKK-1
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
WO2010129752A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both

Similar Documents

Publication Publication Date Title
JP2012523417A5 (ja)
HRP20171992T1 (hr) Protutijela protiv cgrp
JP2013542194A5 (ja)
HRP20191678T1 (hr) Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena
JP2015514110A5 (ja)
SI3042917T1 (en) PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION
JP2020500538A5 (ja)
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
JP2013529183A5 (ja)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2013542191A5 (ja)
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
NZ603972A (en) Anti-fgfr2 antibodies
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
JP2015535828A5 (ja)
TN2012000416A1 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
NZ610734A (en) Human antibodies to the glucagon receptor
NZ628943A (en) Human antibodies to clostridium difficile toxins
NZ705848A (en) Anti-cd38 antibodies
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
RU2015110981A (ru) Комбинации и их применение
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof